However, based on clinical experience, Kaletra dose increase to 533/ 133 mg (4 capsules) twice daily may be considered when co-administered with nevirapine, particularly for patients in whom reduced lopinavir susceptibility is likely.
Baseret på klinisk erfaring, kan en stigning i Kaletra dosis til 533/ 133 mg (4 kapsler) to gange dagligt overvejes, når det gives sammen med nevirapin, særligt til patienter, der har en sandsynlig nedsat lopinavir følsomhed.